Five-Year Real-World Outcomes of Hymenoptera Venom Immunotherapy: Clinical Effectiveness and Immunological Modifications.

Claudia Panzera, Sebastiano Gangemi, Luisa Ricciardi

Abstract readObservational Study

In one paragraph

Observational study in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Claudia PanzeraAllergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.ORCID 0009-0006-3272-4152

Sebastiano GangemiAllergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.

Luisa RicciardiAllergy and Clinical Immunology Unit of G. Martino Hospital, Department of Clinical and Experimental Medicine, University of Messina, 98124 Messina, Italy.ORCID 0000-0003-3105-8347

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hymenoptera venom allergy is a cause of anaphylaxis, which significantly affects patients' daily lives due to the constant fear of accidental stings. Venom immunotherapy (VIT) is the only treatment capable of preventing severe systemic reactions (SSRs). Limited long-term real-life data are available, integrating both clinical and immunological outcomes. A five-year prospective observational study was conducted on 35 patients with a history of SSR who underwent VIT at a tertiary allergy center in Southern Italy; two of them had a diagnosis of systemic mastocytosis. Most patients were sensitized to Vespula, but others to Apis,

Indexed as

Arthropod VenomsDesensitization, ImmunologicHymenopteraInsect Bites and StingsVenom HypersensitivityAdultAgedAnaphylaxisAnimalsFemaleHumansImmunoglobulin EMaleMiddle AgedProspective StudiesTreatment OutcomeArthropod VenomsImmunoglobulin ETryptasesanaphylaxisApisHymenoptera venom allergy (HVA)Polistes dominulatryptasevenom immunotherapy (VIT)venom-specific IgEVespa crabroVespula

Identifiers

PMID42043051

DOI10.3390/toxins18040187

PMCPMC13120408

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.